1. Nyxoah launches Genio system for Obstructive Sleep Apnea in the Netherlands. 2. First implants performed successfully at leading hospitals in Amsterdam and Heerlen. 3. Genio offers non-invasive therapy, enhancing treatment options for OSA patients. 4. The launch signifies growth and validation of Nyxoah's European expansion strategy. 5. Genio's advantages include MRI compatibility and easy upgrades, appealing to healthcare providers.
FAQ
Why Bullish?
The successful launch and implementation of Genio expands Nyxoah's market share. Historical precedent shows similar product launches correlate with positive stock performance.
How important is it?
The article indicates a strategic milestone that could significantly enhance Nyxoah's growth potential and market position.
Why Long Term?
As new treatments are adopted, growth becomes integrated into revenue streams over time. Previous successful launches lead to sustained price increases in the long run.
Nyxoah Launches Genio® Therapy in the Netherlands
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) has officially announced the commercial launch of its innovative Genio® therapy system in the Netherlands. This launch follows the successful implantation of the Genio system at OLVG West Hospital in Amsterdam and Zuyderland Hospital in Heerlen. The timing of this launch is significant as it introduces an alternative treatment option for patients suffering from Obstructive Sleep Apnea (OSA).
Details on the Genio® System
The Genio system represents a breakthrough in the treatment of OSA, employing a unique neuromodulation approach that is leadless and battery-free. Key features of the Genio system include:
- No internal battery, ensuring longevity and ease of use.
- Compatibility with 1.5 and 3T MRI machines.
- An external activation chip for easy upgrades.
- Stimulates both branches of the nerve, enhancing treatment efficacy.
Expert Commentary on Genio® Introduction
Dr. Peter van Maanen, an ENT surgeon at OLVG West, stated, “We are pleased to offer our patients an additional treatment option for OSA when CPAP is not tolerated. With Genio, patients finally have a real choice.” He emphasized that this system promises to be a long-term solution for patients and healthcare providers alike.
Similarly, Dr. Jos Straetmans from Zuyderland Hospital mentioned, “The introduction of Genio expands our ability to tailor therapy to individual patient needs, making it a valuable addition to our treatment options.”
Company Insights and Future Plans
According to Olivier Taelman, Nyxoah's CEO, the launch of Genio in the Netherlands is a crucial milestone in their European rollout strategy. “We are proud to partner with leading Dutch centers to provide an effective and patient-centric alternative to CPAP therapy,” he remarked. The company aims to validate Genio’s efficacy further as a long-term solution for OSA during this expansion phase.
About Nyxoah and Its Innovations
Nyxoah is dedicated to developing pioneering solutions for the treatment of OSA, a condition linked to serious health risks. The Genio system has been clinically validated through the successful completion of the BLAST OSA study and is CE marked since 2019. The company has also secured FDA approval as a prescription-only device for specific adult patients with moderate to severe OSA.
In addition, Nyxoah has conducted successful IPOs on both Euronext Brussels and NASDAQ, allowing for increased growth and development of its innovative OSA treatment solutions. This expansion not only underscores the company's commitment to improving patient outcomes but also positions NYXH as a leader in the medical technology space.
Contact Information
For additional details, visit Nyxoah's official website.
For media inquiries:
- John Landry, CFO: IR@nyxoah.com
- Rémi Renard, Chief Investor Relations & Corporate Communication Officer: IR@nyxoah.com